PACB - 2018 Q3

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission File Number 001-34899

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 



 

Delaware

16-1590339

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)



 

1305 O’Brien Drive

Menlo Park, CA 94025

94025

(Address of principal executive offices)

(Zip Code)

(650) 521-8000

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

 

 



 

 

 

Large accelerated filer

Accelerated filer   



 

 

 

Non-accelerated filer

 

Smaller reporting company

Emerging growth company       

 

 



 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of shares outstanding of the issuer’s common stock as of October 31, 2018: 148,901,892   


 

Table of Contents

 

TABLE OF CONTENTS







 



PAGE No.



 

PART I - FINANCIAL INFORMATION

 



 

Item 1. Financial Statements (unaudited):

 



 

Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017 



 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2017 



 

Condensed Consolidated Statements of Cash Flows for the Nine Months  Ended September 30, 2018 and 2017 



 

Notes to Condensed Consolidated Financial Statements 



 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 

21 



 

Item 3. Quantitative and Qualitative Disclosures About Market Risk 

29 



 

Item 4. Controls and Procedures 

29 



 

PART II. OTHER INFORMATION

 



 

Item 1. Legal Proceedings 

30 



 

Item 1A. Risk Factors 

31 



 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 

54 



 

Item 3. Default Upon Senior Securities 

54 



 

Item 4. Mine Safety Disclosures 

54 



 

Item 5. Other Information 

54 



 

Item 6. Exhibits 

54 







2

 


 

Table of Contents

 

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Balance Sheets

(Unaudited)







 

 

 

 

 



 

 

 

 

 



September 30,

 

December 31,

(in thousands, except per share amounts)

2018

 

2017

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

38,063 

 

$

16,507 

Investments

 

77,684 

 

 

46,365 

Accounts receivable

 

6,404 

 

 

13,433 

Inventory

 

19,694 

 

 

23,065 

Prepaid expenses and other current assets

 

2,028 

 

 

2,249 

Total current assets

 

143,873 

 

 

101,619 

Property and equipment, net

 

34,490 

 

 

37,920 

Long-term restricted cash

 

4,500 

 

 

4,500 

Other long-term assets

 

43 

 

 

45 

Total assets

$

182,906 

 

$

144,084 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

$

5,966 

 

$

9,093 

Accrued expenses

 

9,298 

 

 

12,618 

Deferred service revenue, current

 

5,740 

 

 

6,319 

Other liabilities, current

 

645 

 

 

605 

Total current liabilities

 

21,649 

 

 

28,635 

Deferred service revenue, non-current

 

1,016 

 

 

1,075 

Deferred rent, non-current

 

13,949 

 

 

14,453 

Notes payable, non-current

 

14,384 

 

 

13,635 

Financing derivative

 

28 

 

 

183 

Total liabilities

 

51,026 

 

 

57,981 



 

 

 

 

 

Commitments and contingencies

 

 

 

 

 



 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred Stock, $0.001 par value:

 

 

 

 

 

Authorized 50,000 shares; No shares issued or outstanding 

 

 —

 

 

 —

Common Stock, $0.001 par value:

 

 

 

 

 

Authorized 1,000,000 shares; Issued and outstanding 148,894 and 116,277 shares at September 30, 2018 and December 31, 2017, respectively

 

149 

 

 

116 

Additional paid-in-capital

 

1,083,062 

 

 

965,752 

Accumulated other comprehensive loss

 

(24)

 

 

(32)

Accumulated deficit

 

(951,307)

 

 

(879,733)

Total stockholders’ equity

 

131,880 

 

 

86,103 

Total liabilities and stockholders’ equity

$

182,906 

 

$

144,084 



 

 

 

 

 

See accompanying notes to the condensed consolidated financial statements.

3

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)











 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



Three Months Ended September 30,

 

Nine Months Ended September 30,

(in thousands, except per share amounts)

2018

 

2017

 

2018

 

2017

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Product revenue

$

15,150 

 

$

20,343 

 

$

49,917 

 

$

58,185 

Service and other revenue

 

3,010 

 

 

3,202 

 

 

9,183 

 

 

10,348 

Total revenue

 

18,160 

 

 

23,545 

 

 

59,100 

 

 

68,533 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

12,250 

 

 

11,547 

 

 

31,127 

 

 

31,064 

Cost of service and other revenue

 

2,718 

 

 

3,771 

 

 

8,623 

 

 

12,304 

Total cost of revenue

 

14,968 

 

 

15,318 

 

 

39,750 

 

 

43,368 

Gross profit

 

3,192 

 

 

8,227 

 

 

19,350 

 

 

25,165 

Operating expense:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

14,356 

 

 

15,844 

 

 

46,331 

 

 

49,698 

Sales, general and administrative

 

13,506 

 

 

13,952 

 

 

43,383 

 

 

44,722 

Total operating expense

 

27,862 

 

 

29,796 

 

 

89,714 

 

 

94,420 

Operating loss

 

(24,670)

 

 

(21,569)

 

 

(70,364)

 

 

(69,255)

Interest expense

 

(616)

 

 

(633)

 

 

(1,795)

 

 

(2,297)

Other income, net

 

242 

 

 

181 

 

 

396 

 

 

125 

Net loss

 

(25,044)

 

 

(22,021)

 

 

(71,763)

 

 

(71,427)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

Unrealized income (loss) on investments

 

(8)

 

 

14 

 

 

 

 

(7)

Comprehensive loss

$

(25,052)

 

$

(22,007)

 

$

(71,755)

 

$

(71,434)



 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

$

(0.19)

 

$

(0.19)

 

$

(0.55)

 

$

(0.70)

Shares used in computing basic and diluted net loss per share

 

135,130 

 

 

115,771 

 

 

130,302 

 

 

102,117 



 

 

 

 

 

 

 

 

 

 

 



See accompanying notes to the condensed consolidated financial statements.



4

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)





 

 

 

 

 



 

 

 

 

 



Nine Months Ended September 30,

(in thousands)

2018

 

2017

Cash flows from operating activities

 

 

 

 

 

Net loss

$

(71,763)

 

$

(71,427)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

Depreciation

 

5,436 

 

 

6,632 

Amortization of debt discount and financing costs

 

749 

 

 

931 

(Gain) loss on derivative

 

(155)

 

 

640 

Stock-based compensation

 

15,631 

 

 

14,962 

Other items

 

(398)

 

 

36 

Changes in assets and liabilities

 

 

 

 

 

Accounts receivable

 

7,029 

 

 

2,524 

Inventory

 

3,014 

 

 

(4,027)

Prepaid expenses and other assets

 

537 

 

 

7,361 

Accounts payable

 

(2,926)

 

 

432 

Accrued expenses

 

(3,497)

 

 

(6,001)

Deferred service revenue

 

(638)

 

 

(1,202)

Other liabilities

 

(464)

 

 

1,821 

Net cash used in operating activities

 

(47,445)

 

 

(47,318)

Cash flows from investing activities

 

 

 

 

 

Purchase of property and equipment

 

(1,796)

 

 

(9,373)

Disposal of property and equipment

 

 —

 

 

Purchase of investments

 

(104,228)

 

 

(74,591)

Sales of investments

 

2,442 

 

 

3,662 

Maturities of investments

 

70,680 

 

 

68,071 

Net cash used in investing activities

 

(32,902)

 

 

(12,229)

Cash flows from financing activities

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

4,181 

 

 

8,818 

Notes payable principal payment

 

 —

 

 

(4,500)

Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs

 

 —

 

 

11,865 

Proceeds from issuance of common stock from underwritten public equity offering, net of issuance costs

 

97,722 

 

 

52,530 

Net cash provided by financing activities

 

101,903 

 

 

68,713 

Net increase in cash and cash equivalents and restricted cash

 

21,556 

 

 

9,166 

Cash and cash equivalents and restricted cash at beginning of period

 

21,007 

 

 

21,265 

Cash and cash equivalents and restricted cash at end of period

$

42,563 

 

$

30,431 

Cash and cash equivalents at end of period

 

38,063 

 

 

25,931 

Restricted cash at end of period

 

4,500 

 

 

4,500 

Cash and cash equivalents and restricted cash at end of period

$

42,563 

 

$

30,431 



 

 

 

 

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

Inventory transferred to property and equipment

$

664 

 

$

1,460 

Changes in unpaid property and equipment

$

215 

 

$

846 

Property and equipment paid by landlord

$

 —

 

$

12,600 

Changes in deposits for property and equipment paid in prior period

$

 —

 

$

9,694 

Property and equipment returned to landlord

$

 —

 

$

1,854 

See accompanying notes to the condensed consolidated financial statements.

 

5

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1. OVERVIEW

We design, develop and manufacture sequencing systems to help scientists resolve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT®) sequencing technology, our products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Our technology provides high accuracy, ultra-long reads, uniform coverage and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing.

Our most advanced products offered today include the Sequel instrument and the Sequel SMRT Cell 1M, which together are capable of sequencing up to approximately one million DNA molecules simultaneously. We are continuously developing new products including what we refer to as the SMRT Cell 8M, which is designed to have up to eight times as much throughput capability as the current Sequel SMRT Cell 1M.  We anticipate starting beta testing of the SMRT Cell 8M in early 2019 and launching this new product more broadly some months thereafter.

The names “Pacific Biosciences,” “PacBio,” “SMRT,” “SMRTbell,” “Sequel” and our logo are our trademarks.



NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

In the opinion of management, our accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) have been prepared on a consistent basis with our December 31, 2017 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the entire year or any future periods.

The consolidated financial statements include the accounts of Pacific Biosciences and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Our estimates include, but are not limited to, the valuation of inventory, revenue valuation, the valuation of a financing derivative and long-term notes, the valuation and recognition of share-based compensation, the expected renewal period for service contracts, the useful lives assigned to long-lived assets, and the computation of provisions for income taxes. Actual results could differ materially from these estimates.

Fair Value of Financial Instruments

The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. The carrying value of our other liabilities, non-current, approximates fair value due to the time to maturity and prevailing market rates.

The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs that may be used to measure fair value are as follows:

·

Level 1: quoted prices in active markets for identical assets or liabilities;

·

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are

6

 


 

Table of Contents

 

not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

·

Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

  

We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.

We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of September 30, 2018 and December 31, 2017 respectively (in thousands):







 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



September 30, 2018

 

December 31, 2017

(in thousands)

Level 1

 

Level 2

 

Level 3

 

Total

 

Level 1

 

Level 2

 

Level 3

 

Total

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

$

27,386 

 

$

 —

 

$

 —

 

$

27,386 

 

$

14,858 

 

$

 —

 

$

 —

 

$

14,858 

Commercial paper

 

 —

 

 

10,677 

 

 

 —

 

 

10,677 

 

 

 —

 

 

1,649 

 

 

 —

 

 

1,649 

Total cash and cash equivalents

 

27,386 

 

 

10,677 

 

 

 —

 

 

38,063 

 

 

14,858 

 

 

1,649 

 

 

 —

 

 

16,507 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

 —

 

 

51,633 

 

 

 —

 

 

51,633 

 

 

 —

 

 

20,394 

 

 

 —

 

 

20,394 

Corporate debt securities

 

 —

 

 

9,068 

 

 

 —

 

 

9,068 

 

 

 —

 

 

9,034 

 

 

 —

 

 

9,034 

US government & agency securities

 

 —

 

 

16,983 

 

 

 —

 

 

16,983 

 

 

 —

 

 

16,937 

 

 

 —

 

 

16,937 

Total investments

 

 —

 

 

77,684 

 

 

 —

 

 

77,684 

 

 

 —

 

 

46,365 

 

 

 —

 

 

46,365 

Long-term restricted cash:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

4,500 

 

 

 —

 

 

 —

 

 

4,500 

 

 

4,500 

 

 

 —

 

 

 —

 

 

4,500 

Total assets measured at fair value

$

31,886 

 

$

88,361 

 

$

 —

 

$

120,247 

 

$

19,358 

 

$

48,014 

 

$

 —

 

$

67,372 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financing derivative

$

 —

 

$

 —

 

$

28 

 

$

28 

 

$

 —

 

$

 —

 

$

183 

 

$

183 

Total liabilities measured at fair value

$

 —

 

$

 —

 

$

28 

 

$

28 

 

$

 —

 

$

 —

 

$

183 

 

$

183 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The estimated fair value of the Financing Derivative liability was determined using Level 3 inputs, or significant unobservable inputs.





During the nine months ended September 30, 2018, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

We determined the fair value of the Notes from the debt facility that we entered into during the first quarter of 2013 using Level 3 inputs, or significant unobservable inputs. The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using 9.2% and 10.3% weighted average market yield at September 30, 2018 and December 31, 2017, respectively. Refer to “Note 5. Notes Payable” for additional details regarding the Notes. The estimated fair value and carrying value of the Notes are as follows (in thousands):

7

 


 

Table of Contents

 

The estimated fair value and carrying value of the Notes are as follows (in thousands):









 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



September 30, 2018

 

December 31, 2017



Fair Value

 

Carrying Value

 

Fair Value

 

Carrying Value

Notes payable

$

15,973 

 

$

14,384 

 

$

15,664 

 

$

13,635 



Net Loss per Share

The following outstanding common stock options, restricted stock units, or “RSUs”, with time-based vesting and RSUs with performance-based vesting were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect. See “Note 7. Stockholders’ Equity” for detailed information on RSUs with time-based vesting and RSUs with performance-based vesting.





 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 



 

Nine Months Ended September 30,

 

 

(in thousands)

 

2018

 

2017

 

 

 

 

Options to purchase common stock

 

27,397 

 

25,133 

 

 

 

 

RSUs with time-based vesting

 

349 

 

 —

 

 

 

 

RSUs with performance-based vesting

 

634 

 

 —

 

 

 

 



Concentration and Other Risks

For the three and nine months  ended September 30, 2018, one of our customers, Gene Company Limited, accounted for approximately 20% and 28% of our total revenue, respectively. For the three and nine months  ended September 30, 2017, the same customer, Gene Company Limited, accounted for approximately 35% and 30% of our total revenue, respectively. Gene Company Limited is our distributor in China. 

Going Concern

Cash, cash equivalents and investments, excluding restricted cash, at September 30, 2018 totaled $115.7 million, compared to $62.9 million at December 31, 2017. We believe that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating requirements for at least twelve months from the filing of this Quarterly Report on Form 10-Q; however, we may need to raise additional capital in the future. Our view regarding sufficiency of cash and liquidity is primarily based on our operating plans and financial forecast for 2018, which includes various assumptions regarding demand for our products.

Factors that may affect our capital needs include, but are not limited to, slower than expected adoption of our products resulting in lower sales of our products and services; future acquisitions; our ability to obtain new collaboration, distribution and customer arrangements; the progress of our research and development programs; initiation or expansion of research programs and collaborations; litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; the purchase of patent licenses; and other factors.

To the extent we raise additional funds through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders. There can be no assurance that such funds will be available on favorable terms, or at all, particularly in light of restrictions under our debt agreement. If adequate funds are not available, we may be required to obtain funds by entering into collaboration, licensing or debt agreements on unfavorable terms.  If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, or to increase or maintain the level of our research and development activities.  If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of or eliminating some or all of our development programs.  We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products or cease operations. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements, and we are unable to raise capital, it would have a material adverse effect on our business, financial condition and results of operations.

Significant Accounting Policies

Except as noted below relating to our adoption of ASC 606, there have been no material changes to our significant accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2017.



Recent Accounting Pronouncements

8

 


 

Table of Contents

 

Recently Issued Accounting Standards

In June 2018, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, to simplify the accounting for nonemployee share-based payment transactions by expanding the scope of Accounting Standards Codification, or ASC, Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. Under the new standard, most of the guidance on stock compensation payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. This standard is effective for annual reporting periods beginning after December 15, 2018, including interim reporting periods within those annual reporting periods, with early adoption permitted. We expect to adopt this standard beginning in 2019. While we continue to assess the potential impact of this standard, we do not expect the adoption of this standard to have a material impact on our condensed consolidated financial statements.

In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that allows for an entity to elect to reclassify the income tax effects on items within accumulated other comprehensive income resulting from U.S. tax reform to retained earnings. The guidance is effective for fiscal years beginning after December 15, 2018 with early adoption permitted, including interim periods within those years. We are currently evaluating the impact of this standard on our Consolidated Financial Statements and whether we will make the allowed election.

In February 2016, the FASB issued ASU 2016-02, Leases. The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements - Leases (Topic 842)”. This update provides an optional transition method that allows entities to elect to apply the standard prospectively at its effective date, versus recasting the prior periods presented. If elected, an entity would recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements. We intend to adopt the optional transition method and we expect to adopt this standard beginning in 2019. We do not expect that this standard will have a material impact on our operating results, but we do expect that upon adoption, it will have a material impact on our assets and liabilities. The primary effect of adoption will be the requirement to record right-of-use assets and corresponding lease obligations for current operating leases. We are currently quantifying the impact of adoption.

Recently Adopted Accounting Standards

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. ASU 2016-18 is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. We adopted this standard effective January 1, 2018 using the retrospective transition method by restating our condensed consolidated statements of cash flows to include restricted cash of $4.5 million in the beginning and ending cash, cash equivalents, and restricted cash balances for all periods presented. As a result of adoption, net cash flows for the nine months ended September 30, 2017 did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows. 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” as modified by subsequently issued ASUs 2015-14, 2016-08, 2016-10, 2016-12 and 2016-20 (collectively ASC 606). ASC 606 superseded existing revenue recognition standards with a single model unless those contracts are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The revenue recognition principle in ASC 606 is that an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. On January 1, 2018, we adopted ASC 606 using the modified retrospective method with the cumulative effect of adoption recognized as an adjustment to our accumulated deficit on January 1, 2018. Prior period financial statements and disclosures have not been restated and continue to be reported under the accounting standards in effect for those periods. The adoption of ASC 606 did not have a material impact on our condensed consolidated financial position, results of operations, equity or cash flows as of the adoption date or for the three and nine months  ended September 30, 2018. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

Upon adopting ASC 606, the incremental direct costs of obtaining a contract are now deferred and amortized over the period of contract performance or a longer period if renewals are expected and the renewal commission is not commensurate with the

9

 


 

Table of Contents

 

initial commission. We classify deferred commissions as current and included it in “Prepaid expenses and other current assets” in our condensed consolidated balance sheets.

The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):





 

 

 

 

 

 

 

 

Balance Sheet

Balance at December 31, 2017

 

Adjustments Due to ASC 606

 

Balance at January 1, 2018

Assets

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

$

2,249 

 

$

189 

 

$

2,438 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Accumulated deficit

 

(879,733)

 

 

189 

 

 

(879,544)



In accordance with ASC 606, the disclosure of the impact of adoption on our condensed consolidated statement of operations and comprehensive loss, condensed consolidated balance sheets, and condensed consolidated statements of cash flows is as follows (in thousands):





 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Three Months Ended September 30, 2018

 

Nine Months Ended September 30, 2018

Statement of Operations and Comprehensive Loss

As Reported

 

Balances Without Adoption of ASC606

 

Effect of Change Higher/(Lower)

 

As Reported

 

Balances Without Adoption of ASC606

 

Effect of Change Higher/(Lower)

Operating Expense:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales, general and administrative

$

13,506 

 

$

13,518 

 

$

(12)

 

$

43,383 

 

$

43,430 

 

$

(47)











 

 

 

 

 

 

 

 



As of September 30, 2018

Balance Sheet

As Reported

 

Balances Without Adoption of ASC606

 

Effect of Change Higher/(Lower)

Assets

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

$

2,028 

 

$

1,792 

 

$

236 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Accumulated deficit

$

(951,307)

 

$

(951,071)

 

$

236 









 

 

 

 

 

 

 

 



Nine Months Ended September 30, 2018

Statement of Cash Flows

As Reported

 

Balances Without Adoption of ASC606

 

Effect of Change Higher/(Lower)

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

Net loss

$

(71,763)

 

$

(71,810)

 

$

47 

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

$

537 

 

$

490 

 

$

47 



At September 30, 2018, we had $0.2 million of deferred commissions included in “Prepaid expenses and other current assets” which will be recognized as the related revenue is recognized. Additionally, as a practical expedient, we expense costs to obtain a contract as incurred if the amortization period would have been a year or less.

10

 


 

Table of Contents

 

A summary of our revenue by category for the three and nine months  ended September 30, 2018 and 2017 is as follows (in thousands):











 

 

 

 

 

 

 

 

 

 

 



Three Months Ended September 30,

 

Nine Months Ended September 30,

(in thousands)

2018

 

2017 (1)

 

2018

 

2017 (1)

Instrument revenue

$

6,296 

 

$

9,716 

 

$

21,965 

 

$

29,468 

Consumable revenue

 

8,854 

  

 

10,627 

 

 

27,952 

  

 

28,717 

Product revenue

 

15,150 

 

 

20,343 

 

 

49,917 

 

 

58,185 

Service and other revenue

 

3,010 

 

 

3,202 

 

 

9,183 

 

 

10,348 

Total revenue

$

18,160 

 

$

23,545 

 

$

59,100 

 

$

68,533 



 

 

 

 

 

 

 

 

 

 

 



 

(1)

As noted above, prior period amounts have not been adjusted under the modified retrospective method.



A summary of our revenue by geographic location for the three and nine months  ended September 30, 2018 and 2017 is as follows (in thousands):







 

 

 

 

 

 

 

 

 

 

 



Three Months Ended September 30,

 

Nine Months Ended September 30,



2018

 

2017 (1)

 

2018

 

2017 (1)

North America

$

8,960 

 

$

9,115 

 

$

25,974 

 

$

30,127 

Europe (including the Middle East and Africa)

 

2,914 

  

 

3,197 

 

 

10,614 

  

 

10,430 

Asia Pacific

 

6,286 

  

 

11,233 

 

 

22,512 

 

 

27,976 

Total

$

18,160 

  

$

23,545 

 

$

59,100 

 

$

68,533 









(1)

As noted above, prior period amounts have not been adjusted under the modified retrospective method.



Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; Service and other revenue consist primarily of revenue earned from product maintenance agreements with some additional revenue from instrument lease agreements and grant revenue.

We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Taxes we collect concurrent with revenue-producing activities are excluded from revenue.

Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument accessories, installation, training, and consumables. Additionally, our instrument sale arrangements generally include a one-year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our customers cannot benefit from the system without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment. 

The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price (“SSP”). The SSP is determined based on observable prices at which we separately sell the products and services. If an SSP is not directly observable, then we will estimate the SSP by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs.

11

 


 

Table of Contents

 

We recognize revenues as the performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return.

Contract liabilities and contract assets - Contract liabilities primarily consist of deferred revenue. We record deferred service revenues when cash payments are received or due in advance of our performance for product maintenance agreements. Deferred service revenue is recognized over the related performance period, generally one to three years, on a straight-line basis as the Company is standing ready to provide services and a time-based measure of progress best reflects the satisfaction of the performance obligation. As of September 30, 2018, we had a total of $6.7 million of deferred service revenue from our service contracts, $5.7 million of which was recorded as “deferred service revenue, current” to be recognized over the next year and the remaining $1.0 million was recorded as “deferred service revenue, non-current” to be recognized in the next 2 to 5 years. Revenue recorded in the nine months ended September 30, 2018 includes $5.5 million of previously deferred revenue that was included in “deferred service revenue, current” as of December 31, 2017. Contract assets as of December 31, 2017 and September 30, 2018 were not material.

Instrument lease agreements - Instrument leases are generally classified as operating-type leases and revenue from these leases is recognized on a straight-line basis over the respective lease term, once the lessee takes (or has the right to take) control/possession of the property under the lease. Effectively, this occurs once the installation is complete and control of the instrument is transferred to our customers.

Other practical expedients and exemptions - Customers generally are invoiced upon acceptance of the system, which is also the start of the one-year service period. As such, there is typically not more than a one-year difference between the receipt of cash and the provision of services.  Therefore, we apply the practical expedient and do not account for any potential significant financing benefit.   However, it is noted that some customers will pre-order extended service periods at the time of the initial system sale. These customers may choose to make quarterly or annual payments or prepay multiple years of service upfront but there is no pricing difference between these different payment options.  As such, no significant financing component is believed to exist with any of our existing arrangements.



12

 


 

Table of Contents

 

NOTE 3. CASH, CASH EQUIVALENTS AND INVESTMENTS

The following tables summarize our cash, cash equivalents and investments as of September 30, 2018 and December 31, 2017 (in thousands):







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



As of September 30, 2018 



 

 

Gross

 

Gross

 

 



Amortized

 

unrealized

 

unrealized

 

Fair



Cost

 

gains

 

losses

 

Value

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

$

27,386 

 

$

 —

 

$

 —

 

$

27,386 

Commercial paper

 

10,679 

 

 

 —

 

 

(2)

 

 

10,677 

Total cash and cash equivalents

 

38,065 

 

 

 —

 

 

(2)

 

 

38,063 

Investments:

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

51,647 

 

 

 —

 

 

(14)

 

 

51,633 

Corporate debt securities

 

9,070 

 

 

 —

 

 

(2)

 

 

9,068 

US government & agency securities

 

16,989 

 

 

 —

 

 

(6)

 

 

16,983 

Total investments

 

77,706 

 

 

 —

 

 

(22)

 

 

77,684 

Total cash, cash equivalents and investments

$

115,771 

 

$

 —

 

$

(24)

 

$

115,747 

Long-term restricted cash:

 

 

 

 

 

 

 

 

 

 

 

Cash

$

4,500 

 

$

 —

 

$

 —

 

$

4,500 



 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



As of December 31, 2017 



 

 

Gross

 

Gross

 

 



Amortized

 

unrealized

 

unrealized

 

Fair



Cost

 

gains

 

losses

 

Value

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

$

14,858 

 

$

 —

 

$

 —

 

$

14,858 

Commercial paper

 

1,649 

 

 

 —

 

 

 —

 

 

1,649 

Total cash and cash equivalents

 

16,507 

 

 

 —

 

 

 —

 

 

16,507 

Investments:

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

20,408 

 

 

 —

 

 

(14)

 

 

20,394 

Corporate debt securities

 

9,043 

 

 

 —

 

 

(9)

 

 

9,034 

US government & agency securities

 

16,946 

 

 

 —

 

 

(9)

 

 

16,937 

Total investments

 

46,397 

 

 

 —

 

 

(32)

 

 

46,365 

Total cash, cash equivalents and investments

$

62,904 

 

$

 —

 

$

(32)

 

$

62,872 

Long-term restricted cash:

 

 

 

 

 

 

 

 

 

 

 

Cash

$

4,500 

 

$

 —

 

$

 —

 

$

4,500 



 

 

 

 

 

 

 

 

 

 

 



The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September 30, 2018:





 

 



 

 

(in thousands)

Fair Value

Due in one year or less

$

85,383 

Due after one year through 5 years

 

2,978 

Total investments

$

88,361 



Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.



13

 


 

Table of Contents

 

NOTE 4. BALANCE SHEET COMPONENTS



Inventory



As of September 30, 2018 and December 31, 2017, our inventory consisted of the following components:







 

 

 

 

 



 

 

 

 

 



September 30,

 

December 31,

(in thousands)

2018

 

2017

Purchased materials

$

7,557 

 

$

8,884 

Work in process

 

7,367 

 

 

9,994 

Finished goods

 

4,770 

 

 

4,187 

Inventory

$

19,694 

 

$

23,065 



For the three months ended September 30, 2018 we recognized approximately $2.4 million of product transition costs including inventory reserve taken on older consumables as new products were introduced in 2018. 







NOTE 5. NOTES PAYABLE

As of September 30, 2018, payments due under our notes payable, which include interest and principal, are as follows:







 

 



Amount

Years ending December 31,

(in thousands)

Remainder of 2018

$

353 

2019

 

1,400 

2020

 

16,491 

Total remaining payments

 

18,244 

Less: interest and discounts

 

(3,860)

Notes payable

$

14,384 









NOTE 6. COMMITMENTS AND CONTINGENCIES

As of September 30, 2018, the future annual minimum lease payments under noncancelable operating leases with remaining term in excess of one year are as follows:











 

 



Amount

Years ending December 31,

(in thousands)

Remaining of 2018

$

1,719 

2019

 

6,930 

2020

 

7,056 

2021

 

7,272 

2022

 

7,488 

Thereafter

 

39,222 

Total minimum lease payments

$

69,687 



Rent expense for three and nine months  ended September 30, 2018 was $1.6 million and $4.7 million, respectively. Rent expense for three and nine months  ended September 30, 2017 was $1.6 million and $4.7 million, respectively; 

Legal



USITC Proceedings

14

 


 

Table of Contents

 

On November 2, 2016, we filed a complaint against Oxford Nanopore Technologies Ltd. (“ONT Ltd.”), Oxford Nanopore Technologies, Inc. (“ONT Inc.”) and Metrichor, Ltd. (“Metrichor” and, together with ONT Ltd. and ONT Inc., “ONT”) with the U.S. International Trade Commission (“USITC”) for patent infringement. On December 5, 2016, the USITC provided notice that an investigation had been instituted based on the complaint. We sought exclusionary relief with respect to several ONT products, including ONT’s MinION and PromethION devices. The complaint was based on our U.S. Patent No. 9,404,146, entitled “Compositions and methods for nucleic acid sequencing” which covers novel methods for sequencing single nucleic acid molecules using linked double-stranded nucleic acid templates, providing improved sequencing accuracy. On March 1, 2017, we filed an amended complaint to add a second patent in the same patent family, U.S. Patent No. 9,542,527, which was granted on January 10, 2017, to the investigation. We sought, among other things, an exclusion order permanently barring entry of infringing ONT products into the United States, and a cease and desist order preventing ONT from advertising and selling infringing products in the United States. On May 23, 2017, the Administrative Law Judge (“ALJ”) assigned to the matter issued an order construing certain claim terms of the asserted patents. On June 8, 2017, ONT filed a summary determination motion to terminate the proceedings based on the ALJ’s claim construction decision, and we did not oppose the motion. The ALJ granted the motion on July 19, 2017, and, on July 31, 2017, we filed a petition to review with the USITC to correct what we believe was an incorrect construction of the claims. On September 5, 2017, the USITC issued a notice granting our petition to review the ALJ’s claim construction decision. On February 7, 2018, the USITC issued a notice indicating that it had determined to adopt the ALJ’s claim construction and terminating the investigation. On February 13, 2018, we filed a petition to appeal the USITC’s ruling to the U.S. Court of Appeals for the Federal Circuit.



U.S. District Court Proceedings

On March 15, 2017, we filed a complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-275 (“275 Action”)). The complaint is based on our U.S. Patent No. 9,546,400 (the “’400 Patent”), entitled “Nanopore sequencing using n-mers” which covers novel methods for nanopore sequencing of nucleic acid molecules using the signals from multiple monomeric units. This patent was granted on January 17, 2017. We are seeking remedies including injunctive relief, damages and costs. On May 8, 2017, the defendants filed a motion to dismiss the complaint, alleging that the asserted patent claims recite patent ineligible subject matter. On November 9, 2017, the judge denied ONT Inc.’s motion to dismiss. On June 1, 2018, we filed a motion for leave to amend the complaint to add ONT Ltd. as a defendant.  On August 20, 2018, the judge granted our motion, and on August 23, 2018, we filed an amended complaint, adding ONT Ltd. as a defendant in the 275 Action.  On September 24, 2018, ONT Ltd. filed a motion to dismiss the amended complaint, alleging failure to state a claim.

On September 12, 2018, ONT Inc. filed its answer, defenses and counterclaims in the 275 Action, seeking declaratory judgements of non-infringement and invalidity of the  ’400 Patent and unenforceability of the 400 Patent based on alleged inequitable conduct before the U.S. Patent and Trademark Office (“USPTO”), as well as antitrust, false advertising, and unfair competition counterclaims. On September 25, 2018, it was stipulated that the motion to dismiss ONT Inc.’s counterclaims that we submitted in the 1353 Action would also serve as our motion to dismiss ONT Inc.’s counterclaims in the 275 Action. 

Related to the 275 Action, on March 15, 2018, ONT Inc. filed a petition to institute an inter partes review with the Patent Trial and Appeal Board (“PTAB”) of the USPTO, alleging invalidity of the 400 Patent.  On July 5, 2018, we filed a preliminary response outlining for the PTAB why the petition should be denied, and no review should be instituted.  On September 25, 2018, the PTAB denied ONT Inc.’s petition for institution of the inter partes review for all claims of the 400 Patent.

On September 25, 2017, we filed a second complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-1353 (“1353 Action”)). The complaint is based on our U.S. Patent No. 9,678,056 (the “’056 Patent”) entitled “Control of Enzyme Translation in Nanopore Sequencing”, granted June 13, 2017, and U.S. Patent No. 9,738,929 (the “’929 Patent”) entitled “Nucleic Acid Sequence Analysis”, granted August 22, 2017. We are seeking remedies including injunctive relief, damages and costs. On December 14, 2017, the defendants filed a motion to dismiss the complaint, alleging that the asserted patent claims in the 929 Patent recite patent ineligible subject matter. On March 22, 2018, the judge denied ONT Inc.’s motion to dismiss. On March 28, 2018, we added a claim for infringement of our U.S. Patent No. 9,772,323 (the “323 Patent”), entitled “Nanopore sequencing using n-mers.” On June 1, 2018, we filed a motion for leave to amend the complaint to add ONT Ltd. as a defendant. On August 20, 2018, the judge granted our motion, and on August 23, 2018 we filed an amended complaint, adding ONT Ltd. as a defendant in the 1353 Action.  On September 24, 2018, ONT filed a motion to dismiss the amended complaint, alleging failure to state a claim.

On April 25, 2018, ONT Inc. filed its answer, defenses and counterclaims in the 1353 Action, seeking declaratory judgements of non-infringement and invalidity of the 056 and 323 Patents and unenforceability of the 056 and 323 Patents based on alleged inequitable conduct before the USPTO, as well as antitrust, false advertising, and unfair competition counterclaims. On June 15, 2018, we filed a motion to dismiss ONT Inc.’s counterclaims in the 1353 Action and, on June 18, 2018, we filed a motion to bifurcate and stay discovery on ONT Inc.’s antitrust counterclaims in the 1353 Action.

Related to the 1353 Action, on September 24, 2108, ONT Inc. filed a first petition to institute an inter partes review with the PTAB of the USPTO, alleging invalidity of the 929 Patent.  On September 25, 2018, ONT filed a second petition to institute an

15

 


 

Table of Contents

 

inter partes review of the 929 Patent based on the same art and arguments as the first petition.  We intend to file a preliminary response outlining for the PTAB why the petitions should be denied and no review should be instituted. 

Also related to the 1353 Action, on September 25, 2018, ONT Inc. filed a petition to institute an inter partes review with the PTAB of the USPTO, alleging invalidity of the 056 Patent.  We intend to file a preliminary response outlining for the PTAB why the petition should be denied and no review should be instituted. 

A claim construction (or “Markman”) hearing for the U.S. District Court matters is scheduled to occur on December 17, 2018.  A trial for the U.S. District Court matters is scheduled to occur in March 2020.



UK and German Court Proceedings

On February 2, 2017, we filed a claim in the High Court of England and Wales against ONT Ltd. and Metrichor for infringement of Patent EP(UK) 3 045 542 (the “542 Patent”), which is in the same patent family as the patents asserted in the USITC action referred to above.  We sought remedies including injunctive relief, damages, and costs. On March 27, 2017, the defendants in the case filed their defense and counterclaim, denying infringement and seeking a declaration that the asserted patent is invalid. We filed our reply and defense to counterclaim on April 12, 2017.  A case management conference was held on June 13, 2017.  On August 31, 2017 we added a claim for infringement of a newly granted divisional, EP(UK) 3 170 904 (the “’904 Patent”).   On December 22, 2017, ONT Ltd. added to the action a request for declaration of non-infringement of its 1D2 product. On January 12, 2018 we served reply to ONT Ltd.’s request for a declaration of non-infringement, asserting infringement of both patents by ONT’s 1D2 product. A trial for these matters was scheduled to occur in May 2018. 

On April 21, 2017, ONT Ltd. and Harvard University filed a claim against us in the High Court of England and Wales for infringement of Patent EP(UK) 1 192 453 (the “453 Patent”), a patent owned by Harvard University and entitled “Molecular and atomic scale evaluation of biopolymers,” and for which ONT Ltd. alleges it holds an exclusive license.  ONT Ltd. and Harvard University sought remedies including injunctive relief, damages, and costs. On April 25, 2017, ONT Ltd. announced that it also had filed a claim against us in the District Court of Mannheim, Germany, for infringement of the German version of the patent.  On November 2, 2017, we filed our statement of defense in the German infringement matter and we also filed a separate nullity action in Germany to establish that the 453 Patent is invalid.  On December 6, 2017, we filed a cross-complaint in the German infringement matter alleging ONT Ltd.’s infringement in Germany of our 542 Patent.  The trial date for the German infringement matter and cross-complaint was set for July 27, 2018.  A trial for the UK matter was scheduled to occur in March 2019. 

On May 8, 2018, the parties entered a settlement of all UK and German court proceedings pending as of such date. Under the terms of the settlement, ONT agreed not to make, dispose of, use or import any “2D” nanopore sequencing products, or to induce or assist others to carry out a “2D” sequencing process, in the UK or Germany, through the end of 2023. During this time, we agreed not to assert the 542 Patent and 904 Patent against either ONT or its customers in the UK or Germany. Accordingly, the High Court of England and Wales entered an order staying our UK action against ONT through the end of 2023. As part of the settlement, ONT and Harvard University dismissed their UK and German actions under the 453 Patent and agreed not to assert the 453 Patent against us or our customers through the end of 2023. We correspondingly agreed to dismiss our separate German nullity action seeking to invalidate the 453 Patent, which expires on June 22, 2020.

Related to these proceedings, on August 15, 2017, ONT Ltd. filed a notice of opposition to our 542 Patent with the European Patent Office, and on August 16, 2017, an anonymous party filed a second notice of opposition to the same patent, each alleging invalidity of the patent.  On April 5, 2018, we filed our response to the combined opposition. An oral hearing in the matter is scheduled for January 22, 2019.

Also related to these proceedings, on May 16, 2018, ONT Ltd. filed a notice of opposition to our 904 Patent with the European Patent Office alleging invalidity of the 904 Patent. On October 11, 2018, we filed our response to the opposition.

Litigation is inherently unpredictable, and it is too early in the proceedings to predict the outcome of these lawsuits or any impact they may have on us. As such, the estimated financial effect associated with these complaints cannot be made as of the date of filing of this Quarterly Report on Form 10-Q. Litigation is a significant ongoing expense with an uncertain outcome, and has been in the past and may in the future be a material expense for the Company. Management believes this investment is important to protect the Company’s intellectual property position, even recognizing the uncertainty of the outcome.



Other Proceedings

From time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business;

16

 


 

Table of Contents

 

however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.



NOTE 7. STOCKHOLDERS’ EQUITY



Underwritten Public Equity Offerings

In August 2017, we filed a shelf registration statement on Form S-3 with the SEC pursuant to which we may, from time to time, sell up to an aggregate of $150.0 million of our common stock, preferred stock, depository shares, warrants, units or debt securities. On August 18, 2017, the registration statement was declared effective by the SEC, which allows us to access the capital markets for the three-year period following this effective date.

In February 2018, we entered into an underwriting agreement,  relating to the public offering of 12,500,000 shares of our common stock, $0.001 par value per share, at a price to the public of $2.40 per share. Under the terms of the underwriting agreement, we also granted the Underwriters a 30-day option to purchase up to an additional 1,875,000 shares of our common stock, which was subsequently exercised in full, and the offering as well as the sale of shares of common stock subject to the Underwriters’ option, closed in February 2018. In total, we sold 14.4 million shares of our common stock at a price of $2.40 per share. We paid a commission equal to 4% of the gross proceeds from the sale of shares of our common stock under the underwriting agreement. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $33.1 million, which excludes approximately $0.3 million of offering expenses fully paid as of September 30, 2018.  

In September 2018, we entered into an underwriting agreement,  relating to the public offering of 14,117,647 shares of our common stock, $0.001 par value per share, at a price to the public of $4.25 per share. Under the terms of the underwriting agreement, we also granted the Underwriters a 30-day option to purchase up to an additional 2,117,647 shares of our common stock, which was subsequently exercised in full, and the offering as well as the sale of shares of common stock subject to the Underwriters’ option, closed in September 2018. In total, we sold 16.2 million shares of our common stock at a price of $4.25 per share. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock under the underwriting agreement. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $64.9 million, excluding approximately $0.2 million of offering expenses unpaid as of September 30, 2018. 

In total, for the nine months  ended September 30, 2018, we issued 30.6 million shares of our common stock through our equity offerings, resulting in net proceeds of $97.7 million, excluding approximately $0.2 million of offering expenses unpaid as of September 30, 2018.

Subject to certain exceptions set forth in our Facility Agreement, holders of our Notes may elect to receive up to 25% of the net proceeds from financing activities that include an equity component as prepayment of the Notes to be applied first, to accrued and unpaid interest and second, to principal. However, in both February 2018 and September 2018,  holders representing a majority of the aggregate principal amount of the outstanding Notes waived such right in connection with the issuance and sale of shares of common stock in our public offering.



Equity Plans

As of September 30, 2018, we had three active equity compensation plans: the 2010 Equity Incentive Plan (“2010 Plan”), the 2010 Outside Director Equity Incentive Plan (“2010 Director Plan”), and the 2010 Employee Stock Purchase Plan (“ESPP”). Under the 2010 Plan, with the approval of the Compensation Committee of the Board of Directors, we may grant restricted stock, RSU, stock appreciation rights and new shares of common stock upon exercise of stock options.

In January 2018, an additional 5.8 million shares were reserved under the 2010 Plan, an additional 1.2 million shares were reserved under the 2010 Director Plan and an additional 2.3 million shares were reserved under the ESPP.

17

 


 

Table of Contents

 

Stock Options

The following table summarizes stock option activity for all our stock option plans for the nine months  ended September 30, 2018 (in thousands, except per share amounts):



 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

 

Stock Options Outstanding



 

 

 

 

 

 

 

Weighted



Shares available

 

Number

 

 

 

 

average



for grant

 

of shares

 

Exercise price

 

exercise price

Balances, December 31, 2017

6,795 

 

25,404 

 

$

 1.1616.00 

 

$

6.10 

Additional shares reserved 

6,976 

 

 

 

 

 

 

 

 

Options granted

(4,183)